Matinas BioPharma (MTNB) shelved development of a prescription formulation of fish oil three years ago. The tiny company, with a stock that trades for pennies, decided investors would be more interested in its drug delivery technology and a small pipeline of anti-infectives.

But then Amarin (AMRN) happened. Amarin’s stock price soared to all-time highs — adding nearly $5 billion in market cap — on the readout of a large clinical trial showing its proprietary fish oil drug, called Vascepa, cut the risk of bad cardiovascular events like heart attacks and stroke in patients by an astounding 25 percent.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy